Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.

Sally TemrazFarah NassarMiza Salim HammoudDeborah MukherjiEileen M O'ReillyHaifa DboukFadi FarhatMaya CharafeddineWalid FarajMohammad J KhalifehGhassan K Abou-AlfaAli Shamseddine

Published in: Asia-Pacific journal of clinical oncology (2022)

Neoadjuvant FOLFIRINOX is an active regimen for patients with LA/BR PDAC with a resection rate of 22.5%. These results are in line with prior data.

Keyphrases

locally advanced
rectal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
phase ii study
early stage
electronic health record
big data
data analysis
lymph node
artificial intelligence
open label
deep learning
study protocol